QA: Scynexis INC in us_pharma/2014

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001178253_2015_Scynexis_INC.pdf

Logs

warning No LiabilitiesAndStockholdersEquity node found input.sec.calculation_linkbase.edgar_model_mapping {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'DeferredFinanceCostsNet', 'OtherAssetsNoncurrent', 'DeferredOfferingCosts', 'CashAndCashEquivalentsAtCarryingValue', 'AccountsReceivableNetCurrent', 'UnbilledContractsReceivable', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'DeferredRevenueNoncurrent', 'DerivativeLiabilitiesNoncurrent', 'DeferredRentCreditNoncurrent', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'DeferredRevenueCurrent', 'LongTermDebtCurrent', 'CommonStockValueOutstanding', 'StockholdersEquity', 'AdditionalPaidInCapital', 'RetainedEarningsAccumulatedDeficit'))"}

Graph

Absolute values for 0001178253, Scynexis INC

  xvar xval
0 AssetsCurrent 34,736,000
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 4,835,000
3 remainder_Assets 101,000
4 LiabilitiesCurrent 3,801,000
5 LiabilitiesNoncurrent 0
6 remainder_Liabilities 2,440,000
7 CostOfGoodsAndServicesSold 15,446,000
8 SellingGeneralAndAdministrativeExpense 7,568,000
9 ResearchAndDevelopmentExpense 8,287,000
10 remainder_Expenses -165,000
11 remainder_Revenues 19,024,000
12 remainder_NetIncome 7,878,000
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 39,672,000
1 Liabilities 6,241,000
2 Expenses 31,136,000
3 Revenues 19,024,000
4 StockholdersEquity 33,431,000
5 NetIncome -4,234,000
6 ComprehensiveNetIncome -4,234,000
7 BaseVar 51,975,500
8 EconomicCapitalRatiobeforeLimitedLiability 2.99
9 EconomicCapitalRatio 3.68

Edgar->Model Mapping

Feature Distribution